AFNI Message Board

Dear AFNI users-

We are very pleased to announce that the new AFNI Message Board framework is up! Please join us at:

https://discuss.afni.nimh.nih.gov

Existing user accounts have been migrated, so returning users can login by requesting a password reset. New users can create accounts, as well, through a standard account creation process. Please note that these setup emails might initially go to spam folders (esp. for NIH users!), so please check those locations in the beginning.

The current Message Board discussion threads have been migrated to the new framework. The current Message Board will remain visible, but read-only, for a little while.

Sincerely, AFNI HQ

History of AFNI updates  

Previous Message Next Message
Message List New Topic Print View
|
Claire Wilcox
November 28, 2014 12:28PM
Hello again,

So regarding the first question: the number of trials for one condition is indeed (in fact exactly) three times more than the other condition (9 vs. 27). I've heard FSL can handle this correctly - is there a way for AFNI to handle this?

Regarding the second: you've got it right. I think ASL would be a between subjects variable. Basically, the idea is to correct for changes in blood flow from pre to post medication administration. Group = whether or not they got placebo or active treatment. So I'm thinking that ASL-scan 1 minus ASL-scan 2 could be a between subjects variable.

Thanks again Gang!

Claire
Reply Quote
RSS
Subject Author Posted

3dmema

Claire Wilcox November 18, 2014 12:03PM

Re: 3dmema

gang November 18, 2014 03:13PM

Re: 3dmema

Claire Wilcox November 18, 2014 07:03PM

Re: 3dmema

gang November 19, 2014 10:03AM

Re: 3dmema

Claire Wilcox November 25, 2014 12:03PM

Re: 3dmema

gang November 26, 2014 12:56PM

Re: 3dmema

Claire Wilcox November 28, 2014 12:28PM

Re: 3dmema

gang November 29, 2014 02:13PM

Re: 3dmema

Claire Wilcox December 01, 2014 06:54PM